Sunday, November 22, 2026
21.8 C
Bengaluru

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals, effective July 1, 2026. Based in Singapore, he will additionally serve as Country Division Head for the ASEAN cluster, managing business strategy and operational performance across Southeast Asia.

Asia Pacific, home to over 2.6 billion people, represents one of the most dynamic healthcare regions globally. The growing demand for innovative treatments and evolving patient needs make this a critical market for Bayer’s strategic expansion. In his new role, Rosof will focus on driving growth, strengthening healthcare partnerships, and expanding patient access to innovative medicines throughout the region.

With more than two decades in the pharmaceutical industry, Rosof brings deep expertise in commercial strategy, portfolio management, and general leadership. He previously held senior leadership roles at Bayer and Bristol Myers Squibb, including Senior Vice President and Head of Product & Pipeline in the U.S., where he oversaw commercialization in Oncology, Cardiovascular & Renal, and Women’s Healthcare. His experience spans both marketed products and pipeline assets, along with shaping corporate pharmaceutical strategy at a global level .

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img